1.27
Cassava Sciences Inc (SAVA) 最新ニュース
SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles By Investing.com - Investing.com South Africa
SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles - Investing.com Australia
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Stockholders to Connect - ACCESS Newswire
SAVA stock touches 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
SAVA stock touches 52-week low at $1.34 amid market challenges - Investing.com Australia
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Yahoo Finance
After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs - Being Patient
Is the Future Bleak for SAVA Stock Following Another Setback? - Nasdaq
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - MSN
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful - MSN
Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - MSN
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug By Reuters - Investing.com
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - MSN
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Zacks Investment Research
Cassava ends Alzheimer’s program after simufilam fails again - The Pharma Letter
Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Yahoo Finance
Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data - MarketScreener
Rodman & Renshaw maintains Sell rating on Cassava Sciences stock By Investing.com - Investing.com South Africa
SAVA stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Sector Update: Health Care Stocks Fall Late Afternoon - TradingView
Sector Update: Health Care - MarketScreener
Rodman & Renshaw maintains Sell rating on Cassava Sciences stock - Investing.com India
Top Midday Decliners - MarketScreener
Cassava Sciences Stock: Alzheimer Drug Fails, Program Terminated - Sharewise
Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program - Yahoo Finance
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam - BioSpace
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop - Benzinga
Cassava ends work on Alzheimer’s drug; Alumis gets $40M upfront from Kaken - Endpoints News
Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study - NewsBreak: Local News & Alerts
Cassava stock down as Alzheimer’s program ends (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences shuts down Alzheimer's programshares plummet - Marketscreener.com
SAVA stock touches 52-week low at $2.15 amid market challenges - Investing.com Australia
Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients - MarketScreener
Cassava to discontinue development of Alzheimer’s disease drug - KFGO
Cassava Sciences ends Alzheimer’s treatment development after unsuccessful trials By Investing.com - Investing.com UK
Cassava Sciences stock tumbles after Alzheimer’s drug fails key study By Investing.com - Investing.com Canada
Cassava to discontinue development of Alzheimer's disease drug - MarketScreener
大文字化:
|
ボリューム (24 時間):